J&J : Canada Approves CARVYKTI For Relapsed Or Refractory Multiple Myeloma After 1-3 Prior Therapies
22/11 01:42
(RTTNews) - Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibito...